NMN and Bone Health: The Osteoporosis and NAD+ Connection

Bone Health Guide · Updated June 2026

Osteoporosis affects over 1.2 million Australians, according to the Australian Institute of Health and Welfare. It is the primary driver of fracture risk in older adults — and fractures in older Australians are a leading cause of hospitalisation, loss of independence, and mortality. For the millions of Australians managing bone health, any evidence-based cellular intervention is worth evaluating honestly.

NAD+ and SIRT1 have emerging, documented roles in bone cell biology. This is a real connection, not a marketing extrapolation — though the human clinical evidence specifically for NMN and bone density remains limited.

How SIRT1 and NAD+ Connect to Bone Health

Bone is a dynamic tissue continuously renewed through two processes: bone formation (by osteoblasts) and bone resorption (by osteoclasts). In healthy bone, these are balanced. In osteoporosis, resorption outpaces formation — the skeleton loses mass faster than it is rebuilt.

SIRT1 regulates osteoblast function: SIRT1 — activated by NAD+ — promotes osteoblast differentiation from stem cells and supports osteoblast survival. Research has shown that SIRT1 knockout mice (without SIRT1 function) develop osteoporosis-like bone loss, while SIRT1 activation protects bone density in models of oestrogen-deficiency bone loss (the primary driver of post-menopausal osteoporosis).

SIRT1 regulates the RANKL/OPG ratio: RANKL promotes osteoclast activity (bone resorption); OPG inhibits it. SIRT1 modulates this balance — lower SIRT1 from NAD+ depletion may shift the ratio toward more resorption and less formation.

Inflammation drives bone resorption: Inflammatory cytokines (TNF-α, IL-1β, IL-6) — elevated in inflammageing — directly promote osteoclast activity and bone resorption. The anti-inflammatory effects of both SIRT1 activation (from NAD+) and Quercetin (in the Longevity Complex) may reduce this inflammatory drive to bone loss.

The Evidence — Honestly Assessed

Animal evidence: Multiple studies confirm that NAD+ restoration improves osteoblast function and bone density in mouse models of ageing and oestrogen-deficiency bone loss. This is mechanistically coherent and consistent.

Quercetin and bone — stronger human evidence: Quercetin has published human evidence for bone health effects — specifically anti-osteoporotic activity through osteoblast promotion and osteoclast inhibition. A 2023 study found Quercetin supplementation reduced bone resorption markers in postmenopausal women. This is the strongest human evidence in the Longevity Complex formula for bone-specific outcomes.

NMN and bone in humans — limited: No published human trial has specifically measured NMN's effect on bone mineral density. The SIRT1-bone mechanism is well-characterised; the translation to a human bone density outcome from NMN supplementation specifically remains to be demonstrated.

The Primary Bone Health Interventions

For Australians managing bone health, the evidence-first interventions are:

1. Calcium (1000-1200mg daily) — from food and/or supplements. Test with your GP.
2. Vitamin D3 (with K2) — D3 for calcium absorption; K2 (MK-7 form) directs calcium to bone rather than arteries. Most Australians test deficient despite sun exposure.
3. Weight-bearing exercise — resistance training and weight-bearing aerobic exercise are the most effective interventions for maintaining bone density
4. Magnesium — supports bone mineralisation alongside calcium and D3

NMN and Quercetin may address cellular mechanisms that complement these primary interventions — but are not substitutes for them. Discuss with your GP if osteoporosis is a primary concern.

FAQ

References: Igarashi M et al., NPJ Aging (2022); SIRT1 bone biology literature; Quercetin bone 2023 trial; AIHW osteoporosis statistics; health.gov.au. Not medical advice — consult your GP for osteoporosis management.